European wound sampling patent

We have been informed that the European Patent Office’s examining division intends to grant a European patent for our wound sampling device. A US patent has already been granted (US 10,687,790) and we now await the formal EPO Decision to Grant.  Non-disruptive sampling from the hydrogel component of the RegeniTherix™ system is central to the capability to derive crucial information on the healing status of a problem wound.

We’re always happy to hear from potential investors and funding partners as well as researchers, universities and networks interested in our products and translational work.

Contact us here